ArticleJournal of neuro-oncology2026
Actin, connexin-43 and GAP-43 expression in gliomas: real-world associations with IDH status, tumor burden and survival.
Article in Journal of neuro-oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundConnexin-43 (Cx43), GAP-43 and actin are involved in cellular communication and cytoskeletal dynamics in gliomas, yet their clinical relevance remains largely unclear. We investigated their expression and association with survival and tumor characteristics in IDH-mutant and IDH-wildtype gliomas.
methods134 adult patients operated for newly diagnosed gliomas WHO grades 2-4 in our center were included. Immunohistochemical expression of Cx43, GAP-43 and actin was assessed. Several clinical parameters, including progression-free (PFS) and overall survival (OS), were acquired from our institutional database.
resultsIn IDH-wildtype tumors, higher Cx43 expression was associated with prolonged OS (p = 0.032). Whereas IDH-mutant gliomas showed significantly lower expression of Cx43 (p = 0.029) compared to IDH-wildtype tumors. Actin expression correlated with prognostically unfavorable higher WHO grade (p < 0.001), IDH-wildtype status (p < 0.001), preoperative contrast enhancement in MRI (p = 0.009) and decreased functional status (p < 0.001). Consequently, stronger actin expression was significantly associated with shorter PFS (7.2 vs. 17.4 months, p < 0.001) and OS (17.1 vs. 81.5 months, p < 0.001). Incidentally diagnosed tumors exhibited reduced GAP-43 expression (p = 0.012). None of the proteins was associated with perioperative complications.
conclusionsUpregulated actin expression is strongly linked to more aggressive glioma behavior and reduced survival. Higher Cx43 expression could sustain an onco-protective role in prognostically unfavorable IDH-wildtype tumors. These findings provide clinically relevant translational evidence for the role of cytoskeletal and connectivity-associated proteins in glioma biology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.